📊 TMO Key Takeaways
Is Thermo Fisher Scientific Inc.. (TMO) a Good Investment?
Thermo Fisher demonstrates solid fundamental health with robust profitability (15% net margin, 17.4% operating margin) and strong free cash flow generation ($6.3B annually, 14.1% FCF margin). The company maintains a healthy balance sheet with 1.89x current ratio and reasonable leverage (0.73x debt-to-equity) despite significant debt load, supported by excellent interest coverage of 21.3x. While modest revenue growth of 3.9% YoY and slight net income decline suggest a maturing business, the combination of operational efficiency, substantial cash generation, and financial stability supports a constructive outlook.
Thermo Fisher shows high-quality fundamentals with resilient revenue growth, strong operating and net margins, and robust free cash flow generation. Liquidity and interest coverage are healthy, suggesting the balance sheet can support ongoing investment, although growth is currently moderate and leverage remains meaningful.
Why Buy Thermo Fisher Scientific Inc.. Stock? TMO Key Strengths
- Strong profitability metrics: 15% net margin and 17.4% operating margin indicate operational excellence and pricing power
- Excellent free cash flow generation: $6.3B FCF with 14.1% FCF margin demonstrates ability to fund growth and return capital
- Solid liquidity position: 1.89x current ratio and 1.53x quick ratio provide buffer for obligations
- Fortress-like interest coverage: 21.3x coverage ratio indicates minimal financial distress risk despite $39.2B long-term debt
- Positive earnings per share growth: 7.3% YoY EPS growth despite flat net income shows share buyback or denominator reduction benefit
- Strong profitability with 17.4% operating margin and 15.0% net margin
- Healthy cash generation with $6.29B in free cash flow and 14.1% FCF margin
- Solid financial health with 1.89x current ratio, 0.73x debt-to-equity, and 21.3x interest coverage
TMO Stock Risks: Thermo Fisher Scientific Inc.. Investment Risks
- Slowing organic revenue growth: 3.9% YoY growth is modest and suggests market saturation or competitive pressures
- Declining net income: -0.3% YoY decline despite revenue growth indicates margin compression or higher costs
- Elevated debt levels: $39.2B long-term debt represents significant leverage despite adequate coverage metrics
- Low gross margin: 6.8% gross margin is unusually thin, leaving limited room for operational errors or pricing pressure
- Return on equity concerns: 12.6% ROE is acceptable but modest for a capital-intensive business
- Net income was essentially flat year over year, indicating earnings growth is slowing relative to revenue
- Long-term debt of $39.17B remains substantial and could limit flexibility if operating conditions weaken
- Reported gross margin of 6.8% appears unusually low relative to operating margin, which may indicate data classification or quality issues to monitor
Key Metrics to Watch
- Revenue growth acceleration or deceleration trends - need to monitor if 3.9% growth is cyclical or structural
- Operating margin stability - track whether 17.4% margin can be maintained amid cost pressures
- Free cash flow conversion and sustainability - ensure $6.3B FCF remains consistent with capital spending needs
- Debt reduction trajectory - monitor whether company uses FCF to delever from 0.73x debt-to-equity ratio
- Return on Equity improvement - track if ROE can expand above 12.6% through operational improvements
- Organic revenue growth and net income growth
- Free cash flow conversion and debt reduction progress
Thermo Fisher Scientific Inc.. (TMO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Thermo Fisher Scientific Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
TMO Profit Margin, ROE & Profitability Analysis
TMO vs Market Sector: How Thermo Fisher Scientific Inc.. Compares
How Thermo Fisher Scientific Inc.. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Thermo Fisher Scientific Inc.. Stock Overvalued? TMO Valuation Analysis 2026
Based on fundamental analysis, Thermo Fisher Scientific Inc.. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Thermo Fisher Scientific Inc.. Balance Sheet: TMO Debt, Cash & Liquidity
TMO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Thermo Fisher Scientific Inc..'s revenue has grown significantly by 14% over the 5-year period, indicating strong business expansion. The most recent EPS of $15.45 reflects profitable operations.
TMO Revenue Growth, EPS Growth & YoY Performance
TMO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.6B | $1.6B | $4.25 |
| Q2 2025 | $10.5B | $1.5B | $4.04 |
| Q1 2025 | $10.3B | N/A | $3.46 |
| Q3 2024 | $10.6B | N/A | $4.25 |
| Q2 2024 | $10.5B | N/A | $3.51 |
| Q1 2024 | $10.3B | N/A | $3.32 |
| Q3 2023 | $10.6B | N/A | $3.79 |
| Q2 2023 | $10.7B | N/A | $3.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Thermo Fisher Scientific Inc.. Dividends, Buybacks & Capital Allocation
TMO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Thermo Fisher Scientific Inc.. (CIK: 0000097745)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TMO
What is the AI rating for TMO?
Thermo Fisher Scientific Inc.. (TMO) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 73% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are TMO's key strengths?
Claude: Strong profitability metrics: 15% net margin and 17.4% operating margin indicate operational excellence and pricing power. Excellent free cash flow generation: $6.3B FCF with 14.1% FCF margin demonstrates ability to fund growth and return capital. ChatGPT: Strong profitability with 17.4% operating margin and 15.0% net margin. Healthy cash generation with $6.29B in free cash flow and 14.1% FCF margin.
What are the risks of investing in TMO?
Claude: Slowing organic revenue growth: 3.9% YoY growth is modest and suggests market saturation or competitive pressures. Declining net income: -0.3% YoY decline despite revenue growth indicates margin compression or higher costs. ChatGPT: Net income was essentially flat year over year, indicating earnings growth is slowing relative to revenue. Long-term debt of $39.17B remains substantial and could limit flexibility if operating conditions weaken.
What is TMO's revenue and growth?
Thermo Fisher Scientific Inc.. reported revenue of $44.6B.
Does TMO pay dividends?
Thermo Fisher Scientific Inc.. pays dividends, with $636.0M distributed to shareholders in the trailing twelve months.
Where can I find TMO SEC filings?
Official SEC filings for Thermo Fisher Scientific Inc.. (CIK: 0000097745) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TMO's EPS?
Thermo Fisher Scientific Inc.. has a diluted EPS of $17.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TMO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Thermo Fisher Scientific Inc.. has a BUY rating with 73% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is TMO stock overvalued or undervalued?
Valuation metrics for TMO: ROE of 12.6% (sector avg: 15%), net margin of 15.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TMO stock in 2026?
Our dual AI analysis gives Thermo Fisher Scientific Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is TMO's free cash flow?
Thermo Fisher Scientific Inc..'s operating cash flow is $7.8B, with capital expenditures of $1.5B. FCF margin is 14.1%.
How does TMO compare to other Market stocks?
Vs Default sector averages: Net margin 15.0% (avg: 12%), ROE 12.6% (avg: 15%), current ratio 1.89 (avg: 1.8).